Further study using larger cohort is needed to confirm whether FLT4, IFNG, IL17C, IL32, and MANSC1 may be used as potential prognostic biomarkers to discriminate early-stage and advanced CRC. This evidence concerns the gene MANSC1 and colorectal carcinoma.